March 2026 — Orange Biotech Consulting Co., Ltd. (“Orange Biotech”) was invited to speak at the China Medical Affairs Conference (CMAC) Annual Meeting held in Suzhou. The company’s CEO delivered a keynote presentation addressing the critical role of data governance in clinical development and corporate decision-making, drawing strong interest from industry leaders and stakeholders.
The presentation, titled “Data Governance: A Critical Capability Shaping Clinical Value and Corporate Resilience,” explored how clinical data should be viewed not merely as scientific output, but as a strategic corporate asset that directly impacts company valuation, financing timelines, and global expansion strategies.
Amid increasing complexity in global clinical trials and tightening regulatory expectations, Orange Biotech emphasized that data quality and consistency have become decisive factors in successful drug development. The keynote introduced a three-layer data governance framework, encompassing Data Quality, Data Risk, and Enterprise Impact, illustrating how clinical risks ultimately translate into business risks.
The company also highlighted the evolving role of Contract Research Organizations (CROs). Rather than serving solely as execution partners, CROs are transitioning into strategic collaborators in risk management and data governance. By engaging early in clinical design, co-developing risk matrices, and strengthening cross-border data integration capabilities, CROs can significantly enhance decision-making quality and reduce development uncertainties.
Orange Biotech noted that as the industry shifts toward a data-driven competitive landscape, a company’s ability to establish robust data governance will be a key determinant of its long-term success in both regulatory and capital markets.
Looking ahead, Orange Biotech will continue to advance its expertise in clinical development strategy, global regulatory planning, and data governance, supporting biotech and pharmaceutical companies in achieving sustainable growth in the global market.
The presentation, titled “Data Governance: A Critical Capability Shaping Clinical Value and Corporate Resilience,” explored how clinical data should be viewed not merely as scientific output, but as a strategic corporate asset that directly impacts company valuation, financing timelines, and global expansion strategies.
Amid increasing complexity in global clinical trials and tightening regulatory expectations, Orange Biotech emphasized that data quality and consistency have become decisive factors in successful drug development. The keynote introduced a three-layer data governance framework, encompassing Data Quality, Data Risk, and Enterprise Impact, illustrating how clinical risks ultimately translate into business risks.
The company also highlighted the evolving role of Contract Research Organizations (CROs). Rather than serving solely as execution partners, CROs are transitioning into strategic collaborators in risk management and data governance. By engaging early in clinical design, co-developing risk matrices, and strengthening cross-border data integration capabilities, CROs can significantly enhance decision-making quality and reduce development uncertainties.
Orange Biotech noted that as the industry shifts toward a data-driven competitive landscape, a company’s ability to establish robust data governance will be a key determinant of its long-term success in both regulatory and capital markets.
Looking ahead, Orange Biotech will continue to advance its expertise in clinical development strategy, global regulatory planning, and data governance, supporting biotech and pharmaceutical companies in achieving sustainable growth in the global market.